AnaptysBioANAB
About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees: 117
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
185% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 13
88% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 32
50% more capital invested
Capital invested by funds: $749M [Q2] → $1.13B (+$377M) [Q3]
18% more funds holding
Funds holding: 135 [Q2] → 159 (+24) [Q3]
1.89% more ownership
Funds ownership: 109.4% [Q2] → 111.29% (+1.89%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
23% less call options, than puts
Call options by funds: $28.5M | Put options by funds: $36.9M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
JP Morgan Anupam Rama 27% 1-year accuracy 16 / 59 met price target | 147%upside $36 | Overweight Maintained | 19 Dec 2024 |
Truist Securities John Lee 0 / 0 met price target | 37%upside $20 | Hold Maintained | 18 Dec 2024 |
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target | 175%upside $40 | Overweight Maintained | 12 Dec 2024 |
Guggenheim Yatin Suneja 33% 1-year accuracy 7 / 21 met price target | 147%upside $36 | Buy Maintained | 12 Dec 2024 |
UBS Eliana Merle 20% 1-year accuracy 3 / 15 met price target | 127%upside $33 | Neutral Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 6 articles about ANAB published over the past 30 days
